Novel DPP-IV-resistant Analogs of GLP-1: The N-terminal Extension of GLP-1 by a Single Amino Acid

被引：0
作者：
Oh, Ji-Yeon [1 ]
Lee, ChangWoo [2 ]
Jang, Sei-Heon [2 ]
Yoo, Seung-Bum [3 ]
Chung, Hye-Shin [1 ]
机构：
[1] Hannam Univ, Dept Biotechnol, Taejon 305811, South Korea
[2] Daegu Univ, Dept Mol Biol, Gyongsan 712714, South Korea
[3] Alteogen Inc, Taejon 305812, South Korea
来源：
BULLETIN OF THE KOREAN CHEMICAL SOCIETY | 2009年 / 30卷 / 10期
关键词：
Glucagon-like peptide-1; Dipeptidlyl peptidase IV; Fe fusion; Type; 2; diabetes; GLUCAGON-LIKE PEPTIDE-1; IN-VITRO; ANTIHYPERGLYCEMIC ACTIVITY; BIOLOGICAL-ACTIVITIES; METABOLIC STABILITY; RECEPTOR; DEGRADATION; VIVO; EXPRESSION; EXENDIN-4;
D O I：
10.5012/bkcs.2009.30.10.2471
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
[No abstract available]
引用
收藏
页码：2471 / 2474
页数：4
相关论文
共 20 条
[1]   A recombinant human glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis [J].
Baggio, LL ;
Huang, QL ;
Brown, TJ ;
Drucker, DJ .
DIABETES, 2004, 53 (09) :2492-2500
[2]   Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1 [J].
Burcelin, R ;
Dolci, W ;
Thorens, B .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1999, 48 (02) :252-258
[3]   The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1 [J].
de Maturana, RL ;
Willshaw, A ;
Kuntzsch, A ;
Rudolph, R ;
Donnelly, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (12) :10195-10200
[4]   Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity [J].
Deacon, CF ;
Knudsen, LB ;
Madsen, K ;
Wiberg, FC ;
Jacobsen, O ;
Holst, JJ .
DIABETOLOGIA, 1998, 41 (03) :271-278
[5]   DEGRADATION OF GLUCAGON-LIKE PEPTIDE-1 BY HUMAN PLASMA IN-VITRO YIELDS AN N-TERMINALLY TRUNCATED PEPTIDE THAT IS A MAJOR ENDOGENOUS METABOLITE IN-VIVO [J].
DEACON, CF ;
JOHNSEN, AH ;
HOLST, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (03) :952-957
[6]   Mechanisms of action of glucagon-like peptide 1 in the pancreas [J].
Doyle, Maire E. ;
Egan, Josephine M. .
PHARMACOLOGY & THERAPEUTICS, 2007, 113 (03) :546-593
[7]  
ENG J, 1992, J BIOL CHEM, V267, P7402
[8]   GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro [J].
Gallwitz, B ;
Ropeter, T ;
Morys-Wortmann, C ;
Mentlein, R ;
Siegel, EG ;
Schmidt, WE .
REGULATORY PEPTIDES, 2000, 86 (1-3) :103-111
[9]   N-terminal His7-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity [J].
Green, BD ;
Mooney, MH ;
Gault, VA ;
Irwin, N ;
Bailey, CJ ;
Harriott, P ;
Greer, B ;
O'Harte, FPM ;
Flatt, PR .
JOURNAL OF ENDOCRINOLOGY, 2004, 180 (03) :379-388
[10]   Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1 [J].
Green, BD ;
Gault, VA ;
Irwin, N ;
Mooney, MH ;
Bailey, CJ ;
Harriott, P ;
Greer, B ;
Flatt, PR ;
OHarte, FPM .
BIOLOGICAL CHEMISTRY, 2003, 384 (12) :1543-1551
12